Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

Bryan Oronsky, Jan Scicinski, Michelle M. Kim, Pedro Cabrales, Michael E. Salacz, Corey A. Carter, Neil Oronsky, Harry Lybeck, Michelle Lybeck, Christopher Larson, Tony R. Reid and Arnold Oronsky

EpicentRx, Inc, Mountain View, CA 94040, USA; boronsky@epicentrx.com (B.O.); lybeck.michelle@gmail.com (M.L.)
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA; michekim@med.umich.edu
Department of Bioengineering UCSD, La Jolla, San Diego, CA 92093, USA; pcabrales@ucsd.edu
KU Medical Center, Kansas University, Kansas City, KS 66160, USA; msalacz@kumc.edu
Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA; corey.carter33@gmail.com
CFLS Data, Mountain View, CA 94040, USA; nco@cflsdata.com
Department of Physiology, Helsinki University, 00100 Helsinki, Finland; harrylybeck@gmail.com
Moores Cancer Center, UCSD, La Jolla, CA 92093, USA; chris.larson.mail@gmail.com (C.L.); tonyreid@ucsd.edu (T.R.R.)
InterWest Partners, Menlo Park, CA 94025, USA; AOronsky@interwest.com
* Correspondence: jscicinski@epicentrx.com; Tel.: +1-650-943-2426

Academic Editors: Gerda Egger and Melanie R. Hassler
Received: 29 April 2016; Accepted: 27 June 2016; Published: 4 July 2016

Abstract: First introduced during the late 1800s, radiation therapy is fundamental to the treatment of cancer. In developed countries, approximately 60% of all patients receive radiation therapy (also known as the sixty percenters), which makes radioresistance in cancer an important and, to date, unsolved, clinical problem. Unfortunately, the therapeutic refractoriness of solid tumors is the rule not the exception, and the ubiquity of resistance also extends to standard chemotherapy, molecularly targeted therapy and immunotherapy. Based on extrapolation from recent clinical inroads with epigenetic agents to prime refractory tumors for maximum sensitivity to concurrent or subsequent therapies, the radioresistant phenotype is potentially reversible, since aberrant epigenetic mechanisms are critical contributors to the evolution of resistant subpopulations of malignant cells. Within the framework of a syllogism, this review explores the emerging link between epigenetics and the development of radioresistance and makes the case that a strategy of pre- or co-treatment with epigenetic agents has the potential to, not only derepress inappropriately silenced genes, but also increase reactive oxygen species production, resulting in the restoration of radiosensitivity.

Keywords: radiotherapy; radiosensitization; epigenetics; DNA methyltransferase inhibition; histone deacetylase inhibition; epigenetic priming; reactive oxygen species (ROS)

1. Introduction

All Men Are Mortal. Socrates Is a Man. Therefore, All Men Are Socrates—Woody Allen

In 1896, the same year that W.C. Roentgen discovered X-rays, the Chicagoan, Dr. Emil Grubbe, became the world’s first radiation oncologist when he treated a recurrent breast cancer patient with radiotherapy (XRT) [1,2]. Since that fateful year, the clinical armamentarium has relied heavily on the incorporation of ionizing radiation to treat cancer, albeit with significant modifications from the initial
prescription in the early 1900s to treat until skin erythema or skin burn [3]. In developed countries, radiation therapy (RT) is one of the most frequently used therapeutic modalities with approximately 60% of all cancer patients receiving it in the course of treatment, even though more often than not, similar to chemotherapy and immunotherapy, success is marred by intrinsic or acquired resistance.

In this review, the term “epigenetics” refers to heritable, but potentially reversible, changes in gene expression or cellular phenotype that occur without alteration to the underlying base pair sequence [4]. Given the reversibility of epigenetic marks, which dynamically regulate gene expression, the nascent field of Episensitization [5,6] has emerged to address the treatment-resistance issue with chemo- and immune-therapies as a means of priming malignant cells to respond (or re-respond) to treatment with epigenetic inhibitors; by extension, the rationale for an episensitization strategy in radiotherapy distilled to a simple clinical syllogism (à la all men are mortal. Socrates is a man. Therefore, Socrates is mortal), is that (1) epigenetic inactivation of beneficial genes contributes to radioresistance (2) unlike genetic mutations, epigenetic alterations are reversible (3) ergo, conclusion, targeting epigenetic enzymes with small-molecule inhibitors should reverse non-responsiveness to radiotherapy.

The Merriam-Webster dictionary defines a syllogism as “a formal argument in logic that is formed by two statements and a conclusion which must be true if the two statements are true”. In this review, the syllogism is intended as a framing device to support a more detailed analysis of the aberrant role of epigenetic gene silencing in radioresistance and potential for therapeutic targeting to radioprime refractory tumors.

Each component of the syllogism, represented as a diagram in Figure 1, is reviewed below.

![Diagram of syllogism](image)

**Figure 1.** According to the conventions of a syllogism, if premise 1 and premise 2 are correct, then the conclusion is valid.

2. **Premise #1: Epigenetic Inactivation of Beneficial Genes Contributes to Radioresistance**

Based on preclinical and clinical evidence two major mechanisms of radioresistance exist and epigenetic alterations may involve both.

2.1. **DNA Repair**

Increased DNA recombinational repair of radiation-damaged DNA facilitates recovery of the cancer cells and contributes to a radioresistant phenotype. Conversely, DNA repair deficient cells are associated with radiation hypersensitivity [7]. The phosphatidylinositol 3-kinases (PI3Ks) and its functional subgroup, phosphatidylinositol 3-kinase-related protein kinases (PIKKs) [8,9], namely ataxia telangiectasia-mutated kinase (ATM) and ataxia telangiectasia and rad3-related kinase (ATR) are the main proteins that repair DNA double strand breaks (DSB) via nonhomologous end joining (NHEJ) and homologous recombination repair (HRR) [10]. Activated ATM kinase accelerates repair of radiation-induced DNA-DSB and, consequently, improves post-irradiation cell survival while inhibition of ATM correlates with the reversal of radioresistance [11]. Epigenetic silencing of phosphatase and tensin homolog (PTEN) on chromosome 10, a tumor suppressor gene that antagonizes the PI3K/AKT pathway [12] has been observed in several human cancers [13,14], which results in
constitutive AKT activation, DNA repair and radioresistance (Figure 2). Epigenetic drugs also hold the potential to eradicate cancer progenitor cells [15].

![Diagram](DNA damage → DN-PK, ATM, ATR → Akt activation → PTEN → DNA repair and cell survival)

**Figure 2.** Molecular mechanisms and targets for Akt-mediated DNA repair. Akt can promote DNA repair and survival, leading to radioresistance.

### 2.2. Hypoxia

In a 1955 landmark study, Thomlinson and Gray [16] demonstrated that hypoxia, present in nearly one-third of all tumors [17], is pathognomonic for malignancy. While in normal tissues median oxygen concentrations range from 40 to 60 mmHg, tumors demonstrate pO₂ fractions as low as ≤2.5 mmHg. By contrast, the lowest observable pO₂ value in normal tissues is 12.5 mm Hg [18]. Low oxygen concentrations are definitively associated with radioresistance, tumor recurrence after radiation therapy, and poor outcomes [19]. The mechanism of hypoxic cell radioresistance is related to oxidative DNA damage from the generation of free radicals. In the absence of oxygen, hydrogen donation from sulfhydryl-containing (-SH) groups readily repairs the damage. In the presence of oxygen the damage is “fixed” or made permanent [20]. Thus, compared to well-oxygenated cells [21], hypoxic cells require an increased radiation dose (by a factor of 2-3) to achieve an equivalent level of cytotoxicity.

Epigenetic changes in normal tissue have been associated with adaptation to long-term transient hypoxia as experienced in ischemia and increased expression of the DNA methyltransferases 1 (DNMT1) and 3b (DNMT3b), directly linked to hypoxia-inducible factor 1α (HIF-1α) [22], may be important in the development of a fibrotic phenotype in the heart [23]. In a further example, the Jumonji-domain dioxygenases, a histone demethylase sub-group, are important factors that are upregulated during hypoxia [24] and in tumors, for example, colorectal cancer [25]. These, specifically Jumonji domain-containing 1a (JMJD1A) and 2b (JMJD2B), dynamically respond to hypoxia through histone methylation thus controlling the assembly of chromatin and thereby gene expression [26]. These factors often affect pathways that are critical to some cancers, for example JMJD1A regulates androgen receptor target genes [27]. Chronic hypoxia has been linked to global hypomethylation [28] resulting in genomic instability and leading to tumorigenesis [29]. Interestingly, these observations are in sharp contrast to the increase in global methylation in normal tissue as a consequence of hypoxia, suggesting that mechanisms involving HIF activation may be of greater importance in tumor but not tissue when exposed to low oxygen [30].

Two types of hypoxia [31] have been recognized: (1) transient or acute (2) continuous or chronic. The former induces stabilization of the oxygen-sensitive subunit, HIF-1α, resulting in transcription of multiple angiogenesis-promoting target genes [32-34] including vascular endothelial growth factors, vascular endothelial growth factor receptors and erythropoietin. The latter is associated with transcriptional repression of tumor suppressors such as p53 via hyperdeacetylation [35] of chromatin, in particular, which correlates with increased aggressiveness and therapeutic resistance (Figure 3).
Figure 3. A simplified schematic of the effects of chronic hypoxia on the transcriptional repression of tumor suppressors such as p53.

Although DNMTs have not been studied clinically as epigenetic agents that specifically target hypoxia, in vitro and in vivo inhibition of DNA methylation in the Von-Hippel Lindau tumor suppressor protein (VHL) promoter region by decitabine led to re-expression of VHL in clear cell renal carcinoma [36]. The accumulation of VHL mimics normoxic conditions under which VHL binds to HIF-1a enabling ubiquitination of HIF-1a and thereby its clearance. These data suggest that apparent reversal of the hypoxic response could be a potential clinical target for DNMTs.

Histone deacetylase (HDAC) inhibitors, particularly types I and II [37], can also influence DNA methylation [38] and reduce HIF transcription through a mechanism that may involve the inhibition of acetylation of the HIF transcription complex [39]. The inhibition of transcription of HIF-1a and HIF-2a through transactivation was not dependent on VHL, suggesting that these agents may have activity in tumors lacking VHL and may augment the hypoxia limiting activity of DNMTs when dosed in combination. The HDAC inhibitors romidepsin [40] and panobinostat [41] have been found to negatively regulate HIF and, by extension, angiogenesis [34], leading to increased chemosensitivity that is mediated perhaps, in part, through vascular normalization and improved therapeutic delivery.

Histone methylation has also been implicated in resistance to XRT. In particular, H3K27 methylation, highly expressed in recurrent glioblastoma after treatment with XRT, has been correlated with poor patient prognosis [42]. Indeed, radioresistant glioblastoma multiforme (GBM) cell populations were sensitized to XRT by Enhancer of Zeste Homolog 2 (EZH2) inhibitors [43].

3. Premise #2: Epigenetic Alterations Are Reversible

Epigenetics is on a continuum between genetic and metabolic mechanisms to alter gene expression. Genetic mechanisms such as mutations that involve direct changes to the DNA code itself, are heritable but relatively unsusceptible to exogenous influence, since mutation is a relatively rare event. Metabolic responses, which may initiate gene expression are responsive to exogenous influences, e.g., chemical substrates, but not heritable. Epigenetic modifications have characteristics of both metabolic and genetic mechanisms because, on the one hand, they are heritable and may persist after the exogenous influence is removed, but, on the other hand, they are also reversible. As defined earlier, epigenetic modifications refer to heritable changes in gene expression that occur without an alteration to the sequence or structure of DNA [4]. If the DNA code is comparable to a hard drive, then the epigenome is its operating system, which provides a selective readout of the information contained in the DNA sequence [44]. Unlike the permanence of genetic changes, epigenetic modifications are, in principle, reversible because no primary DNA sequence changes are implicated [45]. This unique property of reversibility raises the prospect that interventions which act on epigenetic regulators may overcome or even revert the resistant phenotype. The paradox of epigenetic effects is that they are, on the one hand, highly dynamic and subject to changes like metabolic responses and, on the other, stably
conserved [46] like genetic mutations due to maintenance and inheritance mechanisms that propagate the epigenetic alterations across generations of cancer cells (Table 1). The heritable epigenome is DNA methylation-based while modifications to histone acetylation are more flexible [47]. Practically, the induction of stable changes in gene expression and the “memory” or persistence of this non-static epigenetic status quo means that the administration of epigenetic therapies may, in theory, precede (by weeks or months) different treatment modalities such as radiotherapy and/or chemotherapy to decrease the risk of concurrent and possibly overlapping toxicities.

**Table 1.** Reversibility of gene expression changes.

| Change Type           | Susceptible to Induced Change | Reproducible | Reversible | Persistent after Stressor Is Removed | Heritable |
|-----------------------|------------------------------|--------------|------------|--------------------------------------|-----------|
| Genetic               | Limited                      | Partially    | No         | Yes                                  | Yes       |
| Epigenetic            | Yes                          | Yes          | Yes        | Yes                                  | Yes       |
| Metabolic             | Yes                          | Yes          | Yes        | No                                   | No        |

The most studied mechanisms that affect the epigenome are DNA methylation and histone modification.

DNA methylation involves the covalent addition of a methyl group to the 5′ position of cytosine, primarily cytosine-guanine or CpG dinucleotides [48]. The CpG dinucleotide pattern is relatively underrepresented in the mammalian genome but tends to cluster in short CpG-rich regions termed CpG islands (Figure 4) [48].

![Figure 4](image)

**Figure 4.** Schema demonstrating transcriptional repression with DNA methylation on cytosine.

In the cancer cell, unlike the normal cell, most of the CpG dinucleotides at gene promoter regions are methylated [49], which is associated with transcriptional silencing. The mechanism of transcriptional silencing is presumably related to steric hindrance of the bulky methyl groups, which physically block the transcriptional machinery from accessing the DNA [50]. DNA methyltransferases (DNMTs) are the enzymes responsible for DNA methylation. As a maintenance methyltransferase, DNMT1 largely copies the DNA methylation pattern from the parent cell to the daughter cells, whereas the de novo methyltransferase proteins, DNMT3a and DNMT3b, generate new methylation marks in quiescent cells [51].

Due to space limitations in the microscopic nucleus, the length of DNA or chromatin is compacted via “spooling” around the outside of the histone octamer or nucleosome [52]. Posttranslational modifications from specific enzymes that include histone acetyltransferases, histone deacetylases, and
histone methyltransferases influence whether the DNA tightly wrapped around the nucleosomes is accessible to the transcriptional machinery [53]. In effect, acetylation of lysine residues from histone acetyltransferases neutralizes the net positive charge of the histones, which, in turn, loosens its affinity for negatively charged chromatin and ultimately renders the DNA more accessible to the transcriptional machinery [54]. By the same token, histone deacetylases, which remove acetyl groups from lysine residues and thereby increase the electrostatic interactions between the DNA and the histones, prevent access of the transcriptional machinery and repress gene expression [55] (Figure 5).

Thus, in general, hyperacetylated regions of chromatin are transcriptionally active, while hypoacetylated chromatin is silent.

It is for these reasons that treatment with cytosine methylation and histone deacetylation inhibitors may lead to stable (i.e., transgenerational) re-expression of beneficial genes that have been silenced by cancer cells.

The duration of action of epigenetic agents is unknown and differs from targeted therapy. With targeted therapy, inhibition of key signaling enzymes leads to changes in signaling patterns that revert after the pressure of inhibition is withdrawn (or the tumor switches to a redundant pathway during treatment) leading to the development of resistance. It is commonly known that the action of epigenetic agents persists after treatment with an epigenetic agent is discontinued. It is therefore not certain how long epigenetic effects last, but these will depend on (1) the epigenetic event (e.g., DNA methylation versus histone acetylation), (2) the type of tumor and the location of the epigenetic modification, and (3) the pharmacodynamics of the epigenetic agent. For example, bromodomain inhibitors are designed to both bind and degrade the protein thus extending their duration of action. Thus radiosensitization with epigenetic agents opens a window of opportunity for the radiation oncologist to exploit in treating patients.

4. Discussion of Analysis: Targeting Epigenetic Enzymes with Small-Molecule Inhibitors Should Reverse Non-Responsiveness to Radiotherapy

The use of the verb “should” in italics above is intended to express expectation. With the caveat that this specific hypothesis requires testing and validation in prospective trials, the assumption is that epigenetic agents will reverse radioresistance based on preliminary evidence of clinical benefit in patients refractory to chemotherapy and immunotherapy. Indeed, on the premise that chemo-, immune- and radioresistance of cancer cells share common epigenetic mechanisms, scant but promising data from clinical trials demonstrating chemotherapy and immunotherapy priming is presented below.
4.1. Epigenetic Inhibitors as Chemotherapy Primers

In a Phase I/II study of 5-azacitidine and carboplatin 46% of patients with platinum-resistant or refractory ovarian cancer demonstrated durable responses and stable disease (median duration of therapy 7.5 months) [44]. In addition, an ongoing randomized Phase II trial (NCT02096354) called ROCKET with the experimental systemically nontoxic epigenetic agent, RRx-001, followed by irinotecan rechallenge on progression of RRx-001 has resulted in “episensitization”, i.e., tumor resensitization by epigenetic mechanisms to irinotecan in multiple patients [5].

One general mechanism of sensitization to both chemotherapy and radiotherapy involves epigenetic restoration of silenced tumor suppressor genes such as p53 [56] and PTEN. Another mechanism of radio/chemosensitization is through blood vessel normalization, which enhances both oxygenation and drug delivery in tumors [57]. Due to the tortuosity and aberrancy of the tumor vasculature, alteration or “normalization” of the tumor vasculature also correlates with increased T cell infiltration.

There is extensive preclinical literature on chemosensitization through the action of epigenetic agents. Notable examples are combinations of a HDAC inhibitor with a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist [58], and how treatment with both histone deacetylase inhibitors and DNA methyl transferase 1 inhibitors can sensitize drug resistant ovarian cancer cells [59].

4.2. Epigenetic Inhibitors as Immunotherapy Primers

In addition to sensitization of chemotherapy, epigenetic agents (e.g., 5-azacytidine, 5-AZA) have been incorporated in a strategy to prime immunotherapy responses [60,61]. In 5 patients with non-small cell lung cancer (NSCLC) who received 5-azacytidine and entinostat prior to treatment with either anti-programmed death 1 (PD-1) or anti-PD-1 ligand 1 (PD-L1) antibodies, three complete responses and two durable stable diseases were observed [60]. Based on this demonstrated clinical benefit, a pretreatment study with azacitidine and entinostat or azacitidine alone prior to the PD-1 inhibitor nivolumab (NCT01928576) was initiated with the primary endpoint of overall response rate [62,63].

Another example of this immune priming strategy involves combination treatment with the experimental systemically non-toxic pan-epigenetic inhibitor, RRx-001, and the PD-1 inhibitor, nivolumab. Preliminary results from the first cohort of patients in a Phase I dose escalation study called PRIMETIME (NCT02518958) indicate promising safety and activity [64].

4.3. Epigenetic Inhibitors as Radiotherapy Primers

Clinical studies of epigenetic agents acting as radiotherapy primers are few and far between, however a Phase II study of the DNA de-methylator hydralazine and the HDAC inhibitor magnesium valproate was carried out in FIGO stage III cervical cancer patients (NCT00404326). The patients received a combination of hydralazine and magnesium valproate seven days before commencement of the combination therapy of cisplatin and radiation. Although this was a single arm study, and thus comparisons are difficult to make, preliminary results suggested that the combination was effective as all evaluable patients achieved clinical complete response during the external radiation compared to the anticipated 75% rate in historical controls [65].

5. Conclusions

Once almost exclusively considered a gene-centric or genomic disease, evidence indicates that pathognomonic epigenetic alterations are also a hallmark of cancer [66]. These epigenetic alterations serve as a mechanism for the cancer cell to turn off the transcription of genes that mediate susceptibility and therapy response.

Of the manifold challenges in oncology including non-selectivity, clinical toxicity and the heterogeneity of response, the one that is perhaps the most pressing, persistent and pervasive is
the appearance of resistance, either intrinsic or acquired, whichcastsitslongandbaulefushadow [67] over all treatment modalities, including radiotherapy. Radioresistance is particularly insidious because it is currently impossible a priori to predict tumor response, and radiotherapy carries with it the risk of acute as well as chronic toxicities which may manifest months or even years later [68]. Given this potential for long-term harm, several authors have called into question the need for routine RT in indications [69] such as locally advanced breast cancer [70] where, despite an increased risk of cardiac toxicity, secondary cancers, pneumonitis, lymphedema and radiation-induced fatigue [71], and no randomized evidence to demonstrate which patients are likely to significantly benefit, chest wall irradiation is considered standard of care [72]. In the absence of a predictive test or biomarker, epigenetic agents, which relieve transcriptional repression, thereby turning on silenced regulators such as tumor suppressor genes, may a fortiori stack the deck in favor of a successful outcome. Of course, while the 3-D dynamics of the tumor are manifestly too complex to reduce to a one-dimensional epigenetic premise, transcriptional dysregulation and the abnormal epigenetic programming that underlies this dysregulation has emerged as a unifying theme in therapeutic resistance, whatever the modality [73].

As described by Strauss and Figg in the Lancet Oncology [74], the nascent field of Episensitization is at the forefront of a broadly applicable strategy to reverse resistance and prime tumor responses to chemotherapies and immunotherapies in the clinical trial setting with agents such as decitabine, entinostat and RRx-001. Epigenetic priming is perhaps even more likely to improve responses in a radiotherapy context given that HDAC inhibitors [75], decitabine [76], and RRx-001 [77], in particular, all induce oxidative stress, which, in turn, sensitizes cancer cells to the effects of ionizing radiation [78].

Radiosensitization is complementary to a radio-priming strategy since both, in theory, increase the activity of a given dose of ionizing radiation. However, unlike epigenetic radiosensitization [79], which implies concurrent dosing with RT and increases the risk of overlapping adverse events, radio-priming may involve a post-treatment “washout period” of days to weeks with the epigenetic agent to minimize combined toxicities, since the objective, subtly different from a radiosensitizing approach, is to stably reshape the gene expression pattern of the tumor, thereby enhancing its susceptibility to subsequent treatment. Transcriptional modifications due to DNMT or HDAC inhibitor therapy may “carryover” from one sequential treatment period to the next because, despite their potential reversibility, epigenetic marks are stably propagated during mitosis, leading in some cases to long-term retention of particular gene expression patterns [80,81], akin to a kind of epigenetic memory. In other words, reprogramming the cancer cell with DNMT or HDAC inhibitors to a “normal-like” state through the forced re-expression of silenced genes has the potential to provide a durable and stable antitumor “memory” response [82].

This “carryover effect” is assumed to be absent or negligible with a traditional concurrent chemoradiation paradigm. Indeed, historically, the main criticism of radiosensitizers, as a whole, has been the narrow benefit to toxicity ratio: the long and checkered history of radiosensitization includes a laundry list of failures, from the nitroimidazoles and halogenated pyrimidines to cisplatin and 5-fluorouracil (5-FU) as potentiators of radiation toxicity [20,83]. By contrast, pretreatment with reactive oxygen species (ROS)-inducing epigenetic agents may not only limit overlapping toxicities due to separate “time windows” of administration but also radioprotect normal tissues; exposure to oxidative stress has the potential to precondition these tissues against further oxidative stress from RT in the same way that ischemic hearts may adapt to the oxidant injury from ischemia reperfusion [84]. In fact, RRx-001 and the organic arsenic compound darinaparsin, both experimental ROS-generating radiosensitizers, are also associated with protection of normal intestinal crypt epithelial cells from clonogenic death after ionizing radiation [77,85,86].

As data from clinical studies mature and, hopefully, continue to validate episensitization as an important anti-resistance strategy for chemotherapies and immunotherapies, it should extend its boundaries to include radiotherapy so that most, if not all, of the sixty percent of cancer patients (that is, the sixty percenters) who receive it at one time during the course of therapy derive benefit.
Acknowledgments: Funding for this review was provided by EpicentRx, Inc.

Author Contributions: All authors contributed to, wrote and reviewed the manuscript.

Conflicts of Interest: B.O., J.S. and M.L. are employees of EpicentRx, Inc. A.O. is an investor in EpicentRx, Inc. The remaining authors declare no conflict of interest.

References

1. Brady, L.W.; Kramer, S.; Levitt, S.H.; Parker, R.G.; Powers, W.E. Radiation oncology: Contributions of the united states in the last years of the 20th century. *Radiology* **2001**, 219, 1–5. [CrossRef] [PubMed]
2. Grubbé, E.H. Priority in the therapeutic use of X-rays. *Radiology* **1933**, 21, 156–162. [CrossRef]
3. Holsti, L.R. Development of clinical radiotherapy since 1896. *Acta Oncol.* **1995**, 34, 995–1003. [CrossRef] [PubMed]
4. Goldberg, A.D.; Allis, C.D.; Bernstein, E. Epigenetics: A landscape takes shape. *Cell* **2007**, 128, 635–638. [CrossRef] [PubMed]
5. Oronsky, B.T.; Oronsky, A.L.; Lybeck, M.; Oronsky, N.C.; Scicinski, J.J.; Carter, C.; Day, R.M.; Rodriguez Orengo, J.F.; Rodriguez-Torres, M.; Fanger, G.F.; et al. Episensitization: Defying time’s arrow. *Front. Oncol.* **2015**. [CrossRef]
6. Oronsky, B.; Oronsky, N.; Scicinski, J.; Fanger, G.; Lybeck, M.; Reid, T. Rewriting the epigenetic code for tumor resensitization: A review. *Transl. Oncol.* **2014**, 7, 626–631. [CrossRef] [PubMed]
7. Pichierri, P.; Franchitto, A.; Palitti, F. Predisposition to cancer and radiosensitivity. *Genet. Mol. Biol.* **2000**, 23, 1101–1105. [CrossRef] [PubMed]
8. Lempiainen, H.; Halazonetis, T.D. Emerging common themes in regulation of PIKKs and PI3Ks. *EMBO J.* **2009**, 28, 3067–3073. [CrossRef] [PubMed]
9. Durocher, D.; Jackson, S.P. DNA-PK, ATM and ATR as sensors of DNA damage: Variations on a theme? *Curr. Opin. Cell Biol.* **2001**, 13, 225–231. [CrossRef]
10. Jackson, S.P. Sensing and repairing DNA double-strand breaks. *Carcinogenesis* **2002**, 23, 687–696. [CrossRef] [PubMed]
11. Carruthers, R.; Ahmed, S.U.; Strathdee, K.; Gomez-Roman, N.; Amoah-Buahin, E.; Watts, C.; Chalmers, A.J. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of atm kinase. *Mol. Oncol.* **2015**, 9, 192–203. [CrossRef] [PubMed]
12. Ming, M.; He, Y.Y. PTEN in DNA damage repair. *Cancer Lett.* **2012**, 319, 125–129. [CrossRef] [PubMed]
13. Mirmohammadsadegh, A.; Marini, A.; Namibiar, S.; Hassan, M.; Tannapfel, A.; Ruzicka, T.; Hengge, U.R. Epigenetic silencing of the pten gene in melanoma. *Cancer Res.* **2006**, 66, 6546–6552. [CrossRef] [PubMed]
14. Kang, Y.H.; Lee, H.S.; Kim, W.H. Promoter methylation and silencing of pten in gastric carcinoma. *Lab. Invest.* **2002**, 82, 285–291. [CrossRef] [PubMed]
15. Byler, S.; Sarkar, S. Do epigenetic drug treatments hold the key to killing cancer progenitor cells? *Epigenomics* **2014**, 6, 161–165. [CrossRef] [PubMed]
16. Thomlinson, R.H.; Gray, L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. *Br. J. Cancer* **1955**, 9, 539–549. [CrossRef] [PubMed]
17. Kalns, J.; Krock, L.; Piepmeier, E., Jr. The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. *Anticancer Res.* **1998**, 18, 363–367. [PubMed]
18. Vaupel, P.; Schlenger, K.; Knoop, C.; Hockel, M. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. *Cancer Res.* **1991**, 51, 3316–3322. [PubMed]
19. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. *Nat. Rev. Cancer* **2004**, 4, 437–447. [CrossRef] [PubMed]
20. Oronsky, B.T.; Knox, S.J.; Scicinski, J. Six degrees of separation: The oxygen effect in the development of radiosensitizers. *Transl. Oncol.* **2011**, 4, 189–198. [CrossRef] [PubMed]
21. Palcic, B.; Skarsgard, L.D. Reduced oxygen enhancement ratio at low doses of ionizing radiation. *Radiat. Res.* **1984**, 100, 328–339. [CrossRef] [PubMed]
22. Yang, J.; Ledaki, I.; Turley, H.; Gatter, K.C.; Montero, J.C.; Li, J.L.; Harris, A.L. Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. *Ann. N. Y. Acad. Sci.* 2009, 1177, 185–197. [CrossRef] [PubMed]

23. Watson, C.J.; Collier, P.; Tea, I.; Neary, R.; Watson, J.A.; Robinson, C.; Phelan, D.; Ledwidge, M.T.; McDonald, K.M.; McCann, A.; et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. *Hum. Mol. Genet.* 2014, 23, 2176–2188. [CrossRef] [PubMed]

24. Shmakova, A.; Batie, M.; Druker, J.; Rocha, S. Chromatin and oxygen sensing in the context of JmjC histone demethylases. *Biochem J.* 2014, 462, 385–395. [CrossRef] [PubMed]

25. Lohse, B.; Kristensen, J.L.; Kristensen, L.H.; Agger, K.; Helin, K.; Gajhede, M.; Clausen, R.P. Inhibitors of histone demethylases. *Bioorg. Med. Chem.* 2011, 19, 3625–3636. [CrossRef] [PubMed]

26. Pollard, P.; Loenarz, C.; Mole, D.R.; McDonough, M.A.; Gleadle, J.M.; Schofield, C.J.; Ratcliffe, P.J. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. *Biochem. J.* 2008, 416, 387–394. [CrossRef] [PubMed]

27. Loh, Y.H.; Zhang, W.; Chen, X.; George, J.; Ng, H.H. Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. *Genes Dev.* 2007, 21, 2545–2557. [CrossRef] [PubMed]

28. Shahrzad, S.; Bertrand, K.; Minhas, K.; Coomber, B.L. Induction of DNA hypomethylation by tumor hypoxia. *Epigenetics* 2007, 2, 119–125. [CrossRef]

29. Pal, A.; Srivastava, T.; Sharma, M.K.; Mehdiniartta, M.; Das, P.; Sinha, S.; Chattopadhyay, P. Aberrant methylation and associated transcriptional mobilization of alu elements contributes to genomic instability in hypoxia. *J. Cell. Mol. Med.* 2010, 14, 2646–2654. [CrossRef] [PubMed]

30. Thirlwell, C.; Schulz, L.; Dibra, H.; Beck, S. Suffocating cancer: Hypoxia-associated epimutations as targets for cancer therapy. *Clin. Epigenet.* 2011. [CrossRef] [PubMed]

31. Rockwell, S. Oxygen delivery: Implications for the biology and therapy of solid tumors. *Oncol. Res.* 1997, 9, 383–390. [PubMed]

32. Semenza, G.L. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. *Curr. Opin. Genet. Dev.* 1998, 8, 588–594. [CrossRef]

33. Qian, D.Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Verheul, H.M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. *Clin. Cancer Res.* 2006, 12, 634–642. [CrossRef] [PubMed]

34. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. *Cancer Lett.* 2009, 280, 145–153. [CrossRef] [PubMed]

35. Johnson, A.B.; Denko, N.; Barton, M.C. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. *Mutat. Res.* 2008, 640, 174–179. [CrossRef] [PubMed]

36. Alleman, W.G.; Tabios, R.L.; Chandramouli, G.V.; Aprilekova, O.N.; Torres-Cabala, C.; Mendoza, A.; Rogers, C.; Sopko, N.A.; Linehan, W.M.; Vasselli, J.R. The in vitro and in vivo effects of re-expressing methylated von hippel-lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. *Clin. Cancer Res.* 2004, 10, 7011–7021. [CrossRef] [PubMed]

37. Chen, S.; Sang, N. Histone deacetylase inhibitors: The epigenetic therapeutics that repress hypoxia-inducible factors. *J. Biomed. Biotechnol.* 2011. [CrossRef] [PubMed]

38. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. *Epigenomics* 2013, 5, 87–94. [CrossRef] [PubMed]

39. Fath, D.M.; Kong, X.; Liang, D.; Lin, Z.; Chou, A.; Jiang, Y.; Fang, J.; Caro, J.; Sang, N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. *J. Biol. Chem.* 2006, 281, 13612–13619. [CrossRef] [PubMed]

40. Mie Lee, Y.; Kim, S.H.; Kim, H.S.; Jin Son, M.; Nakajima, H.; Jeong Kwon, H.; Kim, K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. *Biochem. Biophys. Res. Commun.* 2003, 300, 241–246. [CrossRef]
41. Fischer, C.; Leithner, K.; Wohleneg, C.; Quehenberger, F.; Bertsch, A.; Olschewski, A.; Olschewski, H.; Hrzenjak, A. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1alpha destabilization. Mol. Cancer 2015. [CrossRef] [PubMed]

42. Wu, T.; Lin, B.; Chang, H.; Chang, C. Radio resistance mechanisms of cancers: An overview and future perspectives. Biol. Med. 2015. [CrossRef]

43. Kim, S.H.; Joshi, K.; Ezharlason, R.; Myers, T.R.; Siu, J.; Gu, C.; Nakano-Okuno, M.; Taylor, D.; Minata, M.; Sulman, E.P.; et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FoxM1-dependent manner. Stem Cell Rep. 2015, 4, 226–238. [CrossRef] [PubMed]

44. Azad, N.; Zahnow, C.A.; Rudin, C.M.; Baylin, S.B. The future of epigenetic therapy in solid tumours—Lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10, 256–266. [CrossRef] [PubMed]

45. Majumdar, S.; Buckles, E.; Estrada, J.; Koochekpour, S. Aberrant DNA methylation and prostate cancer. Curr. Genom. 2011, 12, 486–505. [CrossRef] [PubMed]

46. Tsai, H.C.; Baylin, S.B. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 2011, 21, 502–517. [CrossRef] [PubMed]

47. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 2013, 19, 1438–1449. [CrossRef] [PubMed]

48. Ooi, S.K.; O’Donnell, A.H.; Bestor, T.H. Mammalian cytosine methylation at a glance. J. Cell Sci. 2009, 122, 2787–2791. [CrossRef] [PubMed]

49. Issa, J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4, 988–993. [CrossRef] [PubMed]

50. Medvedeva, Y.A.; Khamis, A.M.; Kulakovskiy, I.V.; Ba-Alawi, W.; Bhuyan, M.S.; Kawaji, H.; Lassmann, T.; Harbers, M.; Forrest, A.R.; Bajic, V.B.; et al. Effects of cytosine methylation on transcription factor binding sites. BMC Genom. 2014. [CrossRef] [PubMed]

51. Hermann, A.; Gowher, H.; Jeltsch, A. Biochemistry and biology of mammalian DNA methyltransferases. Cell. Mol. Life Sci. 2004, 61, 2571–2587. [CrossRef] [PubMed]

52. Alberts, B.; Johnson, A.; Lewis, J. Chromosomal DNA and Its Packaging in the Chromatin Fiber. Microbiol. Mol. Biol. Rev. 2007, 2000, 64, 435–459. [CrossRef] [PubMed]

53. Miremadi, A.; Oestergaard, M.Z.; Pharoah, P.D.; Caldas, C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 2007, 16, R28–R49. [CrossRef] [PubMed]

54. Sterner, D.E.; Berger, S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 2000, 64, 435–459. [CrossRef] [PubMed]

55. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349–352. [CrossRef] [PubMed]

56. Shama, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36. [CrossRef] [PubMed]

57. Carter, C.; Reid, T.; Fisher, G.; Cho-Phan, C.; Kunz, P.; Kaiser, H.; Oronsky, B.; Fanger, G.; Caroen, S.; Parker, C.; et al. O3.8early results: “Rocket” a phase II study of RRX-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer. Ann. Oncol. 2015. [CrossRef]

58. Frew, A.J.; Lindemann, R.K.; Martin, B.P.; Clarke, C.J.; Sharkey, J.; Anthony, D.A.; Banks, K.M.; Haynes, N.M.; Gangatirkar, P.; Stanley, K.; et al. Combination therapy of established cancer using a histone deacetylase inhibitor and atrail receptor agonist. Proc. Natl. Acad. Sci. USA 2008, 105, 11317–11322. [CrossRef] [PubMed]

59. Cacan, E.; Ali, M.W.; Boyd, N.H.; Hooks, S.B.; Greer, S.F. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS ONE 2014, 9, e87455. [CrossRef] [PubMed]

60. Wrangle, J.; Wang, W.; Koch, A.; Assawaran, H.; Mohammad, H.P.; Vendetti, F.; Vancriekinge, W.; Demeyer, T.; Du, Z.; Parsana, P.; et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2015, 4, 2067–2079. [CrossRef] [PubMed]

61. Siglottii, L.; Fratta, E.; Coral, S.; Maio, M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol. Ther. 2014, 142, 339–350. [CrossRef] [PubMed]

62. Juergens, R.A.; Vendetti, F.; Coleman, B.; Sebree, R.S.; Rudek, M.A.; Belinsky, S.A. Phase I trial of 5-azacitidine (SAc) and SNDX-275 in advanced lung cancer (NSCLC). J. Clin. Oncol. 2008, 26. abstract No. 19036.

63. Juergens, R.A.; Wrangle, J.; Vendetti, F.P.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N.; et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1, 598–607. [CrossRef] [PubMed]
64. Carter, C.; Rozwarski, J.; Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA. Unpublished data. 2016.

65. Candelaria, M.; Cetina, L.; Garcia, A.; Wegman-Ostrosky, T.; Robles, E.; González-Fierro, A.; López-Graniel, C.; González, A.; Cantú, D.; Ribera, L.; et al. Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIIB. A phase II study. BMC Cancer 2007. [CrossRef]

66. Herceg, Z.; Hainaut, P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol. Oncol. 2007, 1, 26–41. [CrossRef] [PubMed]

67. Keating, P.; Cambrosio, A.; Nelson, N.C.; Mogoutov, A.; Cointet, J.P. Therapy’s shadow: A short history of the study of resistance to cancer chemotherapy. Front. Pharmacol. 2013. [CrossRef] [PubMed]

68. Hanna, N.; Timmerman, R.; Foster, R.S.; Roth, B.J.; Einhorn, L.H.; Nichols, C.R. Long-term toxicity of radiation therapy. In Holland-Frei Cancer Medicine, 6th ed.; Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Jr., Gansler, T.S., Hamilton (ON): BC Decker, 2003; Available online: http://www.ncbi.nlm.nih.gov/books/NBK13384/ (accessed on 29 June 2016).

69. Jagsi, R. Postmastectomy Radiation Therapy: An Overview for the Practicing Surgeon. ISRN Surg. 2013. [CrossRef] [PubMed]

70. Buchholz, T.A.; Strom, E.A.; Perkins, G.H.; McNeese, M.D. Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist 2002, 7, 539–546. [CrossRef] [PubMed]

71. Shapiro, C.L.; Recht, A. Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 2001, 344, 1997–2008. [PubMed]

72. Haffty, B.G.; Hunt, K.K.; Harris, J.R.; Buchholz, T.A. Positive sentinel nodes without axillary dissection: Implications for the radiation oncologist. J. Clin. Oncol. 2011, 29, 4479–4481. [CrossRef] [PubMed]

73. Oronsky, B.; Oronsky, N.; Knox, S.; Fanger, G.; Scicinski, J. Episensitization: Therapeutic tumor resensitization by epigenetic agents: A review and reassessment. Anticancer Agents Med. Chem. 2014, 14, 1121–1127. [CrossRef] [PubMed]

74. Strauss, J.; Figg, W.D. Epigenetic approaches to overcoming chemotherapy resistance. Lancet Oncol. 2015, 16, 1013–1015. [CrossRef]

75. Rosato, R.R.; Almenara, J.A.; Maggio, S.C.; Coe, S.; Atadja, P.; Dent, P.; Grant, S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol. Cancer Ther. 2008, 7, 3285–3297. [CrossRef] [PubMed]

76. Shin, D.Y.; Park, Y.S.; Yang, K.; Kim, G.Y.; Han, M.H.; Kang, H.S.; Choi, Y.H. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int. J. Oncol. 2012, 41, 910–918. [PubMed]

77. Ning, S.; Bednarski, M.; Oronsky, B.; Scicinski, J.; Saul, G.; Knox, S.J. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012, 72, 2600–2608. [CrossRef] [PubMed]

78. Cook, J.A.; Giuss, D.; Wink, D.A.; Krishna, M.C.; Russo, A.; Mitchell, J.B. Oxidative stress, redox, and the tumor microenvironment. Semin. Radiat. Oncol. 2004, 14, 259–266. [CrossRef] [PubMed]

79. De Schutter, H.; Nuyts, S. Radiosensitizing potential of epigenetic anticancer drugs. Anticancer Agents Med. Chem. 2009, 9, 99–108. [CrossRef] [PubMed]

80. Rada-Iglesias, A. Pioneering barren land: Mitotic bookmarking by transcription factors. Dev. Cell 2013, 24, 342–344. [CrossRef] [PubMed]

81. Kadauke, S.; Blobel, G.A. Mitotic bookmarking by transcription factors. Epigenet. Chromatin 2013. [CrossRef] [PubMed]

82. Tsai, H.C.; Li, H.; Van Neste, L.; Cai, Y.; Robert, C.; Rassool, F.V.; Shin, J.J.; Harbom, K.M.; Beatty, R.; Pappou, E.; et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012, 21, 430–446. [CrossRef] [PubMed]

83. Oronsky, B.T.; Oronsky, N.C.; Fanger, G.R.; Lybeck, M.; Caroen, S.Z.; Parker, C.W.; Scicinski, J. A review of two promising radiosensitizers in brain metastases: RRx-001 and 2-deoxyglucose. J. Cancer Sci. Ther. 2015, 7, 137–141. [CrossRef]

84. Muller, B.A.; Dhalla, N.S. Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemic-reperfused heart. Curr. Cardiol. Rev. 2010, 6, 255–264. [CrossRef] [PubMed]
85. Tian, J.; Doi, H.; Saar, M.; Santos, J.; Li, X.; Peehl, D.M.; Knox, S.J. Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer. *Int. J. Radiat. Oncol. Biol. Phys.* **2013**, *87*, 1179–1185. [CrossRef] [PubMed]

86. Scicinski, J.; Oronsky, B.; Ning, S.; Knox, S.; Peehl, D.; Kim, M.M.; Langecker, P.; Fanger, G. No to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. *Redox Biol.* **2015**, *6*, 1–8. [CrossRef] [PubMed]